Page 3 - Sputnikv Has Proven To Be Quot One Of The Most Effective And Safe Tools Against Covid 19 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sputnikv has proven to be quot one of the most effective and safe tools against covid 19. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sputnikv Has Proven To Be Quot One Of The Most Effective And Safe Tools Against Covid 19 Today - Breaking & Trending Today

Brazilian health regulator Anvisa has approved the import of India's Covaxin jab, which is now waiting for WHO's approval.


by Bhaswati Guha Majumder - Jun 5, 2021 08:45 AM
Bharat Biotech’s COVAXIN 
As India is looking forward to World Health Organization’s (WHO) approval for Hyderabad based Bharat Biotech’s Covaxin jab, the Center said that “the milestone will be achieved soon”.
During a news conference on the Covid-19 situation in India, Dr VK Paul, Member (Health) Niti Aayog, said that the authorities have been working with Bharat Biotech and WHO, data exchange is underway and we are keen that this milestone is accomplished soon.
Meanwhile, on 4 June, Anvisa, which is Brazil s health agency, approved imports of Russia s Sputnik V as well as India s Covaxin (BBV152 COVID-19) vaccinations—but with conditions on both the jabs. ....

United States , Andhra Pradesh , Covaxin Covid , Ministry Of Health , World Health Organization , Member Health Niti Aayog , Bharat Biotech , Niti Aayog , Good Manufacturing Practices , South American , Use Listing , Bharat Biotech The , Emergency Use Authorisations , Covid 19 Vaccine Update , Covid 19 Vaccine News , Who Approval For Bharat Biotech X27s Covaxin , Brazil Covaxin Use , Vaccine News , Covid 19 News , ஒன்றுபட்டது மாநிலங்களில் , ஆந்திரா பிரதேஷ் , அமைச்சகம் ஆஃப் ஆரோக்கியம் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , உறுப்பினர் ஆரோக்கியம் நீதி ஆயோக் , பாரத் பயோடெக் , நீதி ஆயோக் ,

SII wants ''indemnity'' for all vaccine makers; seeks nod to manufacture Sputnik-V


Technology > Biotech & pharma
04 June 2021
Serum Institute of India (SII), the maker of Covishield, the Indian name for Oxford-AstraZeneca s vaccine against the Wuhan virus, has sought indemnity for vaccine failures or side effects on lines demanded by foreign vaccine companies like Pfizer, saying that the government should apply “same rules for all”.
Covishield-maker Serum Institute of India (SII) has asked for indemnity from liability for vaccine makers, whether Indian or foreign, after Pfizer and Moderna have sought protection from litigation.
The Adar Poonawalla-led SII, which is involved in the trials of three new anti-Coronavirus vaccines, has also sought approval from the Drug Controller General of India (DCGI) for the manufacture of the Russian vaccine Sputnik-V. ....

United Kingdom , Committee On Genetic Manipulation , Gamaleya Research Institute Of Epidemiology , National Expert Group On Vaccine Administration , Serum Institute Of India , Department Of Biotechnology , Serum Institute , Drug Controller General , Emergency Use Authorisation , National Expert Group , Vaccine Administration , Gamaleya Research Institute , Review Committee , Genetic Manipulation , Omain B , ஒன்றுபட்டது கிஂக்டம் , குழு ஆன் ஜெநெடிக் கையாளுதல் , சீரம் நிறுவனம் ஆஃப் இந்தியா , துறை ஆஃப் உயிரி தொழில்நுட்பவியல் , சீரம் நிறுவனம் , மருந்து கட்டுப்படுத்தி ஜநரல் , தேசிய நிபுணர் குழு , விமர்சனம் குழு , ஜெநெடிக் கையாளுதல் ,